Alector is a San Francisco, California based company that is headed by Chief Executive Officer Arnon Rosenthal, PhD and Chief Scientific Officer Peter Heutink, PhD. Alector was founded to explore two scientific insights: that the immune system plays a critical role in neurodegenerative diseases, and that redirecting aberrant immune cell activity in the brain could improve healthy function. Our strategy is conceptionally similar to immuno-oncology. Immuno-oncology therapies recruit the peripheral adaptive immune system to counteract tumors. Our immuno-neurology therapies recruit the central innate immune system to counteract brain pathologies. AL001 modulates progranulin (PGRN), a key regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders. We are initially developing AL001 for frontotemporal dementia (FTD) with progranulin mutation (FTD-GRN). The global INFRONT-3 Phase 3 clinical trial is currently enrolling both at-risk and symptomatic participants with FTD-GRN.